![]() |
New to the Huntington's Disease Lighthouse? |
||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HD Lighthouse Contributing Editor's Comment: This Web site will be a wonderful resource for our UK readers who are looking for clinical trials in which to participate plus the information about the research will be of interest to everyone. -- Marsha L. Miller, Ph.D. New website brings latest clinical research news to Huntington's disease familiesDr Ed Wild
The Huntington’s disease clinical research team at the Institute of Neurology, University College, London, announces the launch of a new website that will bring the latest news about clinical research in Huntington’s disease (HD) to patients, relatives and carers in the UK and worldwide. The site, hdresearch.ucl.ac.uk, will be a source of the latest information about all clinical research in HD being carried out through the HD Multidisciplinary Clinic of the National Hospital for Neurology and Neurosurgery, Queen Square, London, by researchers at UCL Institute of Neurology. The site contains:
Dr Sarah Tabrizi is the Lead Consultant Neurologist of the HD Multidisciplinary Clinic and leads HD clinical research at UCL Institute of Neurology. “hdresearch.ucl.ac.uk will move HD research in the UK forward by bringing the latest information about taking part in clinical research straight to the homes of HD gene carriers, their families and carers,” she says. “We expect the site to become an invaluable and trusted resource for our patients to get informed and get involved in HD research” Hundreds of patients and their families already take part in research through the HD Multidisciplinary Clinic, with eight major clinical studies in progress and more on the way. As well as locally-based research, UCL researchers and volunteers are involved in several major international studies, including the Huntington Study Group’s PREDICT-HD project and the European HD Network’s REGISTRY initiative. The team is also closely linked with the UK HD Network and Euro-HD (www.euro-hd.net). “For patient and family volunteers already involved in clinical research, the site is a way of keeping up-to-date with the latest news and exciting projects coming soon. For those who have never taken part in research, the site is a way to find out where HD research is up to, what taking part in research is like and how to get involved. We also hope to reach those HD family members who may want to take part in research but don’t necessarily want to be seen at the HD clinic,” says Dr Tabrizi. Additional Information
For further information contact: Dr Ed Wild Source: Press Release: UCL Institute of Neurology, Queen Square London
|
Research focusing on the formation of aggregates caused by HD
Research related to the role Brain Derived Neurotrophic Factor has on the pathology of HD in the brain
Research related HD and it's general affect on the brain
Research related to drugs and supplements that may delay onset and slow progression of Huntington's Disease.
Research focusing on gene therapy.
Research focusing on gene transcription.
General research related to HD
Research studying the genetics of Huntington's Disease
Research studying the Immune System and it's effect on the progression of HD
Research studying the brain tissue and research related to stem cells
18 Jul 2008
Participants needed for qualitative studies of JHD
The University of Iowa is recruiting participants for two important new studies. 9 Jun 2008
The Research Pipeline - taking drugs from the lab to the clinic
Here's an overview of some of the more promising potential treatments moving through the research pipeline. 12 Mar 2008
Phase III creatine trial
NCCAM and the Orphan Product Division of the FDA is funding a phase III clinical trial of medicinal grade creatine. 1 Oct 2007
ACR16 closer to Phase III clinical trials
Neurosearch applies for permission to start Phase III clinical trials of ACR16, a dopamine stabilizer, in Europe and the U.S. 30 Sep 2007
Research Study for those At Risk
Last call for participants in an At Risk study. 19 Aug 2007
Riluzole Found Ineffective for Huntington's Disease Patients
A Phase III clinical trial of the glutamate blocker riluzole failed to slow progression or improve symptoms in HD patients.
1 Aug 2007
Daniel P. Van Kammen, MD, Phd, to lead CHDI Huntington's Disease Clinical Development Effort
MRSSI, Inc. announced today that Daniel P. van Kammen MD, PhD has joined as Chief Medical Officer.
31 Jul 2007
HD Study for Those At Risk
John Hopkins University and the National Human Genome Research Institute are starting a new study for those at risk.
28 Jul 2007
HSG to Conduct a Phase 2 Study in Adults with Mild-to-Moderate Huntington Disease
HSG announces a Phase II study of Dimebon
5 Feb 2007
Miraxion Study Completed, Results Soon
Amarin Corp. and the HSG have completed a Phase III clinical trial of Miraxion which investigated whether the drug improves motor symptoms in HD.
All Updates for Clinical Trials | ||||||||||||||||||||||
| Disclaimer & Privacy
Policy | |
|